DMAC DiaMedica Therapeutics Inc.
Nasdaq · SEC CIK 1401040 · EDGAR
- Bought, last 12 months
- $7.63M 1 purchases by 1 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 116 since 2021-07-16, latest 2026-08-12 16:23
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| TRILL AB | 10% | $7.63M | — |
| Semba Charles Pauling | Dir | — | — |
| Pauls Dietrich John | Pres, CEO, Dir | — | — |
| Parsons James T. | Dir | — | — |
| Giuffre Randall Michael | Dir | — | — |
Transactions 58
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 16:23 | 2026-08-10 | DMAC | Pauls Dietrich John | Pres, CEO, Dir | A - Grant | $0.00 | +60.2K | 128.8K | +88% | $0 | |
| 2026-01-06 | 2026-01-02 | DMAC | Giuffre Randall Michael | Dir | A - Grant | $8.42 | +6,175 | 398.6K | +2% | +$52.0K | |
| 2026-01-06 | 2026-01-02 | DMAC | Parsons James T. | Dir | A - Grant | $8.42 | +10.1K | 97.9K | +11% | +$85.0K | |
| 2026-01-06 | 2026-01-02 | DMAC | Semba Charles Pauling | Dir | A - Grant | $8.42 | +3,355 | 48.0K | +8% | +$28.2K | |
| MI | 2025-12-08 | 2025-11-17+ | DMAC | TRILL AB | 10% | P - Purchase | $7.19 | +1.06M | 8.50M | +14% | +$7.63M |
| D | 2025-11-25 | 2025-11-21 | DMAC | Parsons James T. | Dir | M - OptEx | $2.20 | +12.0K | 87.9K | +16% | +$26.4K |
| MI | 2025-09-04 | 2025-08-13+ | DMAC | STAHLBERG JAN | 10% | P - Purchase | $5.96 | +1.00M | 7.06M | +17% | +$5.96M |
| I | 2025-07-25 | 2025-07-23 | DMAC | JACINTO RICHARD II | 10% | P - Purchase | $3.50 | +400.0K | 4.96M | +9% | +$1.40M |
| I | 2025-07-25 | 2025-07-23 | DMAC | STAHLBERG JAN | 10% | P - Purchase | $3.50 | +1.54M | 6.76M | +30% | +$5.40M |
| I | 2025-07-25 | 2025-07-23 | DMAC | Von Koch Thomas | 10% | P - Purchase | $3.50 | +2.86M | 8.38M | +52% | +$10.00M |
| D | 2025-04-08 | 2025-04-07 | DMAC | Pilnik Richard D. | Dir | M - OptEx | $2.11 | +24.0K | 313.0K | +8% | +$50.6K |
| DM | 2025-02-18 | 2025-02-13 | DMAC | Giuffre Randall Michael | Dir | M - OptEx | $2.56 | +17.0K | 392.4K | +5% | +$43.6K |
| 2025-01-03 | 2025-01-02 | DMAC | Kuntz Richard | Dir | A - Grant | $5.34 | +9,925 | 24.2K | +69% | +$53.0K | |
| D | 2025-01-03 | 2025-01-02 | DMAC | Parsons James T. | Dir | A - Grant | $5.34 | +15.9K | 75.9K | +27% | +$85.0K |
| 2025-01-03 | 2025-01-02 | DMAC | Pilnik Richard D. | Dir | A - Grant | $5.34 | +10.4K | 289.0K | +4% | +$55.5K | |
| 2025-01-03 | 2025-01-02 | DMAC | Semba Charles Pauling | Dir | A - Grant | $5.34 | +5,290 | 44.6K | +13% | +$28.2K | |
| 2025-01-03 | 2025-01-02 | DMAC | Giuffre Randall Michael | Dir | A - Grant | $5.34 | +10.9K | 375.4K | +3% | +$58.0K | |
| I | 2024-07-01 | 2024-06-28 | DMAC | STAHLBERG JAN | 10% | P - Purchase | $2.50 | +1.20M | 5.22M | +30% | +$3.00M |
| I | 2024-07-01 | 2024-06-28 | DMAC | TomEnterprise Private AB | 10% | P - Purchase | $2.50 | +1.20M | 5.53M | +28% | +$3.00M |
| 2024-01-02 | 2024-01-02 | DMAC | Parsons James T. | Dir | A - Grant | $2.80 | +21.4K | 59.9K | +56% | +$60.0K | |
| 2024-01-02 | 2024-01-02 | DMAC | Kuntz Richard | Dir | A - Grant | $2.80 | +14.3K | 14.3K | New | +$40.0K | |
| 2024-01-02 | 2024-01-02 | DMAC | Giuffre Randall Michael | Dir | A - Grant | $2.80 | +19.2K | 364.6K | +6% | +$53.7K | |
| 2024-01-02 | 2024-01-02 | DMAC | Semba Charles Pauling | Dir | A - Grant | $2.80 | +9,375 | 39.3K | +31% | +$26.2K | |
| 2024-01-02 | 2024-01-02 | DMAC | Pilnik Richard D. | Dir | A - Grant | $2.80 | +30.4K | 278.6K | +12% | +$85.0K | |
| 2023-11-16 | 2023-11-16 | DMAC | Wambeke David J. | Chief Business Off | P - Purchase | $2.46 | +20.0K | 527.1K | +4% | +$49.2K | |
| I | 2023-06-27 | 2023-06-23 | DMAC | TomEqt Private AB | 10% | P - Purchase | $3.40 | +1.47M | 4.33M | +51% | +$5.00M |
| 2023-06-26 | 2023-06-23 | DMAC | Kellen Scott | CFO, Sec | P - Purchase | $3.91 | +10.0K | 32.3K | +45% | +$39.1K | |
| 2023-06-26 | 2023-06-23 | DMAC | Wambeke David J. | Chief Business Off | P - Purchase | $3.91 | +38.4K | 507.1K | +8% | +$150.0K | |
| 2023-06-26 | 2023-06-23 | DMAC | Pilnik Richard D. | Dir | P - Purchase | $3.91 | +38.4K | 248.2K | +18% | +$150.0K | |
| 2023-06-26 | 2023-06-23 | DMAC | Pauls Dietrich John | Pres, CEO, Dir | P - Purchase | $3.91 | +12.8K | 68.6K | +23% | +$50.0K | |
| 2023-06-26 | 2023-06-23 | DMAC | Semba Charles Pauling | Dir | P - Purchase | $3.91 | +12.8K | 29.9K | +75% | +$50.0K | |
| 2023-06-26 | 2023-06-23 | DMAC | Giuffre Randall Michael | Dir | G - Gift | $0.00 | -15.0K | 345.4K | -4% | $0 | |
| 2023-06-26 | 2023-06-23 | DMAC | Giuffre Randall Michael | Dir | P - Purchase | $3.91 | +65.0K | 360.4K | +22% | +$254.2K | |
| D | 2023-04-11 | 2023-04-10 | DMAC | Wambeke David J. | Chief Business Off | P - Purchase | $1.60 | +468.8K | 468.8K | New | +$750.0K |
| 2023-01-03 | 2023-01-03 | DMAC | Burroughs Amy L. | Dir | A - Grant | $1.53 | +17.2K | 73.3K | +31% | +$26.2K | |
| 2023-01-03 | 2023-01-03 | DMAC | Semba Charles Pauling | Dir | A - Grant | $1.53 | +17.2K | 17.2K | New | +$26.2K | |
| 2023-01-03 | 2023-01-03 | DMAC | Giuffre Randall Michael | Dir | A - Grant | $1.53 | +35.1K | 295.4K | +13% | +$53.7K | |
| 2023-01-03 | 2023-01-03 | DMAC | Pilnik Richard D. | Dir | A - Grant | $1.53 | +55.6K | 209.9K | +36% | +$85.0K | |
| M | 2022-12-12 | 2022-12-08+ | DMAC | Giuffre Randall Michael | Dir | P - Purchase | $1.42 | +57.1K | 223.1K | +34% | +$81.0K |
| M | 2022-12-08 | 2022-12-06+ | DMAC | Giuffre Randall Michael | Dir | P - Purchase | $1.40 | +24.9K | 180.6K | +16% | +$34.7K |
| I | 2022-12-06 | 2022-12-02 | DMAC | Von Koch Thomas | 10% | P - Purchase | $1.24 | +2.86M | 2.86M | New | +$3.54M |
| I | 2022-12-06 | 2022-12-02 | DMAC | Von Koch Thomas | 10% | S - Sale | $1.24 | -2.86M | 0 | -100% | -$3.54M |
| 2022-12-05 | 2022-12-01 | DMAC | Giuffre Randall Michael | Dir | P - Purchase | $1.19 | +819 | 178.3K | +0.5% | +$974.61 | |
| 2022-12-05 | 2022-12-05 | DMAC | Pilnik Richard D. | Dir | P - Purchase | $1.39 | +35.0K | 154.3K | +29% | +$48.6K | |
| M | 2022-12-01 | 2022-11-29+ | DMAC | Giuffre Randall Michael | Dir | P - Purchase | $1.20 | +67.2K | 177.5K | +61% | +$80.5K |
| 2022-11-16 | 2022-11-16 | DMAC | Pauls Dietrich John | Pres, CEO, Dir | P - Purchase | $1.21 | +20.0K | 55.8K | +56% | +$24.2K | |
| I | 2022-07-21 | 2022-07-08 | DMAC | TomEnterprise AB | 10% | P - Purchase | $1.33 | +208.0K | 2.86M | +8% | +$276.6K |
| 2022-01-03 | 2022-01-03 | DMAC | Giuffre Randall Michael | Dir | A - Grant | $3.58 | +15.0K | 110.2K | +16% | +$53.8K | |
| 2022-01-03 | 2022-01-03 | DMAC | Burroughs Amy L. | Dir | A - Grant | $3.58 | +11.2K | 56.1K | +25% | +$40.0K | |
| 2022-01-03 | 2022-01-03 | DMAC | Pilnik Richard D. | Dir | A - Grant | $3.58 | +23.8K | 119.3K | +25% | +$85.1K | |
| 2022-01-03 | 2022-01-03 | DMAC | Parsons James T. | Dir | A - Grant | $3.58 | +16.8K | 38.5K | +77% | +$60.0K | |
| 2021-09-15 | 2021-09-15 | DMAC | ALCORN HARRY W JR | SVP, Clinical Ops | P - Purchase | $3.80 | +15.0K | 43.6K | +52% | +$57.0K | |
| 2021-08-17 | 2021-08-16 | DMAC | Burroughs Amy L. | Dir | P - Purchase | $3.15 | +45.0K | 45.0K | New | +$141.6K | |
| M | 2021-08-17 | 2021-08-16 | DMAC | Pilnik Richard D. | Dir | P - Purchase | $3.27 | +15.0K | 83.1K | +22% | +$49.0K |
| 2021-08-16 | 2021-08-16 | DMAC | Kellen Scott | CFO, Sec | P - Purchase | $3.15 | +10.0K | 22.3K | +81% | +$31.5K | |
| 2021-08-16 | 2021-08-16 | DMAC | Pauls Dietrich John | Pres, CEO, Dir | P - Purchase | $3.14 | +5,000 | 35.8K | +16% | +$15.7K | |
| I | 2021-08-16 | 2021-08-16 | DMAC | ALCORN HARRY W JR | Senior VP, Clinical Ops | P - Purchase | $3.07 | +399 | 399 | New | +$1,225 |
| M | 2021-08-16 | 2021-08-16 | DMAC | ALCORN HARRY W JR | Senior VP, Clinical Ops | P - Purchase | $3.09 | +20.3K | 28.3K | +256% | +$62.8K |
Purchase Sale Sale after option exercise All abbreviations